Repligen Corporation (NASDAQ:RGEN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Repligen Corporation (NASDAQ:RGEN) has received a consensus rating of “Moderate Buy” from the sixteen research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eleven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $164.6429.

A number of equities analysts recently weighed in on RGEN shares. Barclays raised their price objective on Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Weiss Ratings cut shares of Repligen from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday. Wolfe Research started coverage on shares of Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price target on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Finally, Royal Bank Of Canada started coverage on shares of Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price objective for the company.

Insider Buying and Selling

In related news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Repligen

Several institutional investors have recently bought and sold shares of RGEN. Iron Triangle Partners LP purchased a new position in shares of Repligen during the third quarter valued at approximately $36,091,000. Hudson Bay Capital Management LP bought a new position in Repligen in the third quarter worth about $2,807,000. Massachusetts Financial Services Co. MA bought a new position in Repligen in the fourth quarter worth about $199,176,000. Cinctive Capital Management LP bought a new position in Repligen in the third quarter worth about $3,398,000. Finally, Royce & Associates LP raised its stake in Repligen by 66.1% in the third quarter. Royce & Associates LP now owns 148,658 shares of the biotechnology company’s stock worth $19,871,000 after buying an additional 59,136 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Price Performance

RGEN stock opened at $147.01 on Friday. The firm has a 50 day simple moving average of $122.84 and a two-hundred day simple moving average of $135.54. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The stock has a market cap of $8.29 billion, a PE ratio of 163.35, a P/E/G ratio of 2.83 and a beta of 1.09. Repligen has a one year low of $100.99 and a one year high of $175.77.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. The company had revenue of $194.26 million during the quarter, compared to the consensus estimate of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The firm’s revenue was up 14.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, analysts predict that Repligen will post 1.99 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.